Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
03/2005
03/03/2005WO2005018646A1 Ophthalmic composition
03/03/2005WO2003102151A3 Modulating cell differentiation and treating myeloprolifertive disorders with jnk/mkk inhibitors
03/03/2005WO2003042362A3 PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR
03/03/2005WO2003031405A3 Methods for the synthesis of substituted purines
03/03/2005US20050050589 Soya cell strains with high isoflavone content
03/03/2005US20050050580 Transgenic animal expressing hla-a24 and utilization thereof
03/03/2005US20050049424 6-Hydroxy isoflavones derivatives and medicaments involving same
03/03/2005US20050049408 That retains the high RNA binding affinity of the parent oligonucleotide N3' --> P5' phosphoramidates and exhibits a much higher acid stability; inhibiting human telomerase enzyme activity; solid phase synthesis; kits
03/03/2005US20050049308 Apolipoprotein D degradation inhibitor
03/03/2005US20050049303 Adamantane derivatives
03/03/2005US20050049293 Increasing effect of released acetylcholine on hepatic muscarinic receptors
03/03/2005US20050049290 Benzimidazole derivatives and their use as gnrh antagonists
03/03/2005US20050049283 Compounds that inhibit factor xa activity
03/03/2005US20050049272 Gastrointestinal disorders; inhibiting gastric acid secretion; such as 2,3-dimethyl-9-(2-ethyl-6-methyl-phenyl)-7H-8,9-dihydro-pyrano[2,3-c]-imidazo[1,2-a]pyridine-6-(N,N-diethyl)carbamide
03/03/2005US20050049268 Use of at least one abl, kit and/or platelet-derived growth factor receptor tyrosine kinases inhibitor for treating hair depigmentation
03/03/2005US20050049265 Use of inhibitors of i$g(k)b kinease for the treatment of cancer
03/03/2005US20050049264 Suppressing growth of abnormal cells; gastric, brain, colon, pancreatic, lung, renal, ovarian and prostatic cancer
03/03/2005US20050049263 Purine analogs having hsp90-inhibiting activity
03/03/2005US20050049261 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo{1,2-a}pyrimidin-5(1h)one derivatives
03/03/2005US20050049258 Enzyme inhibitors for phosphodiesterase isozymes for treatment of asthma, chronic bronchitis and chronic obstructive pulmonary disease
03/03/2005US20050049252 Treating arthritis, pain and cancer; cyclooxygenase-2 inhibitors
03/03/2005US20050049250 7-Aikyl and cycloalkyl-substituted imidazotriazinones
03/03/2005US20050049246 Such as [3-(2-Bromo-ethoxy)-phenyl]-[4-(3-cyclohexyl-5-methyl-isoxazol-4-yl)-pyrimidin-2-yl]-amine
03/03/2005US20050049240 Tetrahydroisochinolines, their production and the use thereof as analgesics
03/03/2005US20050049233 Transdermal administering of testosterone
03/03/2005US20050049231 Local delivery of aromatase inhibitor using intravaginal device; estrogen dependent proliferative disorders of uterus; minimal side effects, longer term treatment, variable dosage
03/03/2005US20050049216 Immunostimulatory nucleic acid molecules
03/03/2005US20050049215 contain unmethylated cytosine-guanine (CpG) dinucleotides; stimulating interferon-alpha to treat viral infections; oligonucleotide linked to a biodegradable delivery complex
03/03/2005US20050049203 Nitrogenous heterocyclic derivative, medicinal composition containing the same, medical use thereof, and intermediate therefor
03/03/2005US20050049202 For treating disorders associated with excessive cytokine release such as interleukin-1 (IL-1) for example infection, cancer, asthma, coronary restenosis, autoimmune disease, cirrhosis, entotoxemia, reperfusion injury and septic shock; lactone or lactam-benzoates or benzamides
03/03/2005US20050049198 Contacting a cardiac ryanodine receptor (RyR2) with a fragment of a dihydropyridine receptor (DHPR) polypeptide; ischemic heart disease, congestive heart failure, cardiac hypertrophy (calcium overload), dysrhythmia, or heart attack, cardiomyopathy
03/03/2005US20050049190 Cation conducting gabaa receptors and their use
03/03/2005US20050048639 Caspase-8 binding protein, its preparation and use
03/03/2005US20050048557 Expression vector comprising nucleotide sequences coding microorganismsal protein for use in developing vaccine agents which prevent bacterial infection; bactericides; microbiocides
03/03/2005US20050048537 Novel human lipocalin homologs and polynucleotides encoding the same
03/03/2005US20050048525 Amino acid sequences having hydrolase enzyme activity for use diagnosis, prevention and treatment of cardiovascular and gastrointestinal disorders; drug screening; bioassay
03/03/2005US20050048511 Truncated glycogen synthase kinase 3 protein for use in identifying modulators to treat diabetes, inflammation and nervous system disorders; drug screening
03/03/2005US20050048479 Adenylyl and guanylyl cyclases
03/03/2005US20050048148 Synergistic mixtures; balancing (pro/anti)inflammatory cytokines
03/03/2005US20050048138 Use of Rhodiola crenulata extract via the topical route
03/03/2005US20050048135 Mixture containing plant extract; renin, angiogenesis inhibitor; cardiovascular disorders; antidiabetic agents; liver disorders; gall stones; gastrointestinal disorders
03/03/2005US20050048128 Using ascorbic acid and petroleum jelly
03/03/2005US20050048104 Transdermal drug delivery devices comprising a polyurethane drug reservoir
03/03/2005US20050048078 Protein polymer having unfold activity on higher-order structure of protein
03/03/2005US20050048070 Mixture of polypeptides from cytokeratins; anticancer agnets; vaccines
03/03/2005US20050048055 Use of CD40 engagement to alter T cell receptor usage
03/03/2005US20050048052 Bioassay for detecting expression of mammalian CC-chemokine receptor 2, by binding of antibody or antigen-binding fragment; human or humanized monoclonal antibody; test kits
03/03/2005US20050048029 Nucleotide sequence for diagnosis, prevention, therapy of cancer, inflammation, autoimmune disease and infections
03/03/2005US20050047958 Methods for sterilizing preparations of digestive enzymes
03/03/2005CA2536313A1 Fused pyrimidine derivative and use thereof
03/03/2005CA2535807A1 Peptides with the capacity to bind to transforming growth factor .beta.1 (tgf-.beta.1)
03/02/2005EP1510579A2 Use of heregulin as an epithelial cell growth factor
03/02/2005EP1510518A2 Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels
03/02/2005EP1510516A1 Pyrazole compound and medicinal composition containing the same
03/02/2005EP1510515A1 Phenylglycine derivatives as serine protease inhibitors
03/02/2005EP1510511A1 Gingerol analogues and use thereof
03/02/2005EP1510224A1 In vivo gene transfer methods for wound healing
03/02/2005EP1510223A1 Intravenous composition, process for producing the same and preparation thereof
03/02/2005EP1510222A2 Medicinal compositions promoting bowel movement
03/02/2005EP1510220A1 Therapeutic inhibitor of vascular smooth muscle cells
03/02/2005EP1510210A1 Immunity-related protein kinase inhibitors
03/02/2005EP1510209A1 Therapeutic agent for inflammatory intestinal diseases containing hydroxamic acid compound as active ingredient
03/02/2005EP1509621A1 Treatment with cytokines for alzheimer's disease
03/02/2005EP1509618A2 Autoimmune conditions and nadph oxidase defects
03/02/2005EP1509610A1 Transgenic plants with controlled distribution of a trait to progeny
03/02/2005EP1509597A2 Hair follicle mesenchymal stem cells and use thereof
03/02/2005EP1509541A2 Novel recombinant anticoagulant proteins
03/02/2005EP1509537A2 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds and the compounds as such
03/02/2005EP1509532A1 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
03/02/2005EP1509530A1 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
03/02/2005EP1509529A2 Esters in position 20 of camptothecins
03/02/2005EP1509528A2 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
03/02/2005EP1509526A2 Imidazo(1,2-a)pyrazin-8-ylamines, method of making, and method of use thereof
03/02/2005EP1509521A2 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases
03/02/2005EP1509518A1 Calcium receptor modulating agents
03/02/2005EP1509516A1 Inhibitors of the gpib -vwf interaction, their preparation and use
03/02/2005EP1509515A2 Substituted 4-aryl-4h-pyrrolo 2,3-h chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
03/02/2005EP1509509A1 Glucagon antagonists/inverse agonists
03/02/2005EP1509506A1 Pyridazine derivatives
03/02/2005EP1509499A1 Pyrrole compounds for the treatment of prostaglandin mediated diseases
03/02/2005EP1509498A1 Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
03/02/2005EP1509489A1 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof
03/02/2005EP1509251A2 Nucleic acids, polypeptides, and methods for modulating apoptosis
03/02/2005EP1509249A2 Inclusion complexes of rosiglitazone
03/02/2005EP1509233A1 Liquid formulation of decitabine and use of the same
03/02/2005EP1509230A2 Method of treating cancer using kinase inhibitors
03/02/2005EP1509228A1 Derivatives of 2-(1-benzyl-1h-pyrazolo (3, 4-b)pyridine-3yl) -5-(4-pyridinyl)-4-pyrimidine amine and the use thereof as guanylate cyclase stimulators
03/02/2005EP1509225A1 Method for the use of pyranoindole derivatives to treat infection with hepatitis c virus
03/02/2005EP1509219A1 Methods and compositions for the treatment of graft failure
03/02/2005EP1509217A1 Monotherapy for the treatment of amyotrophic lateral sclerosis with cyclooxygenase-2 (cox 2) inhibitor(s)
03/02/2005EP1509199A1 Dry powder inhalant composition
03/02/2005EP1509188A2 Compounds active at the glucocorticoid receptor ii
03/02/2005EP1416966A4 Methods for treating joint inflammation, pain, and loss of mobility
03/02/2005EP1412353B1 Imidazopyridinones as p38 map kinase inhibitors
03/02/2005EP1296650B1 Methods and compositions for treating pain of the mucous membrane
03/02/2005EP1169065B1 Methacoline or histamine formulations for detecting asthma
03/02/2005EP1137764B1 New medical use of gene and vector encoding a multisubstrate deoxyribonucleosidase
03/02/2005EP1129084B1 Thiazole derivatives as ppar gamma ligands
03/02/2005EP1042279B1 Substituted beta-alanines
03/02/2005EP1030667B1 Use of mirtazapine for the manufacture of a medicament for treating sleep apneas
1 ... 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 ... 1564